FDA Approved Products
4,498 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
RETIN-A
tretinoin
LOE Approaching
Bausch + Lomb
TOPICAL · CREAM
1974
NDA30/100
RETIN-A
tretinoin
LOE Approaching
Bausch + Lomb
TOPICAL · CREAM
1973
NDA30/100
RETIN-A
tretinoin
LOE Approaching
Bausch + Lomb
TOPICAL · SWAB
1971
NDA30/100
RETIN-A MICRO
tretinoin
LOE Approaching
Bausch + Lomb
TOPICAL · GEL
1997
NDA30/100
RETIN-A-MICRO
tretinoin
LOE Approaching
Bausch + Lomb
TOPICAL · GEL
1997
NDA30/100
RETISERT
fluocinolone acetonide
LOE Approaching
Bausch + Lomb
INTRAVITREAL · IMPLANT
2005
NDA30/100
RETROVIR
zidovudine
LOE Approaching
GSK
INJECTION · INJECTABLE
1990
NDA30/100
RETROVIR
zidovudine
LOE Approaching
GSK
ORAL · CAPSULE
1987
NDA30/100
RETROVIR
zidovudine
LOE Approaching
GSK
ORAL · TABLET
1995
NDA30/100
RETROVIR
zidovudine
LOE Approaching
GSK
ORAL · SOLUTION
1989
NDA30/100
REVATIO
sildenafil citrate
LOE Approaching
Viatris (2)
INTRAVENOUS · SOLUTION
2009
NDA30/100
REVATIO
sildenafil citrate
LOE Approaching
Viatris (2)
ORAL · TABLET
2005
NDA30/100
REVEX
nalmefene hydrochloride
LOE Approaching
Hikma
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · SOLUTION
1995
NDA30/100
REVIA
naltrexone hydrochloride
LOE Approaching
Teva
ORAL · TABLET
1984
NDA30/100
REVLIMID
lenalidomide
LOE Approaching
Bristol Myers Squibb
ORAL · CAPSULE
intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality withwithout additional cytogenetic abnormalities+2
2005
NDA30/100
REYATAZ
atazanavir
LOE Approaching
Bristol Myers Squibb
ORAL · CAPSULE
2003
SMNDA30/100
REZULIN
troglitazone
LOE Approaching
R-Pharm US
ORAL · TABLET
1997
NDA30/100
RHINOCORT
budesonide
LOE Approaching
NASAL · SPRAY, METERED
1999
NDA30/100
RHINOCORT
budesonide
LOE Approaching
AstraZeneca
NASAL · AEROSOL, METERED
1994
NDA30/100
RHINOCORT ALLERGY
budesonide
LOE Approaching
NASAL · SPRAY, METERED
1999
NDA30/100
RID MOUSSE
piperonyl butoxide; pyrethrins
LOE Approaching
Bayer
TOPICAL · AEROSOL
2000
NDA30/100
RIDAURA
auranofin
LOE Approaching
Enterprise Therapeutics
ORAL · CAPSULE
1985
NDA30/100
RIFADIN
rifampin
LOE Approaching
Sanofi
ORAL · CAPSULE
asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynxmeningococcal infection because of the possibility of the rapid emergence of resistant organisms+1
1971
NDA30/100
RIFADIN
rifampin
LOE Approaching
Sanofi
INJECTION · INJECTABLE
asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynxmeningococcal infection because of the possibility of the rapid emergence of resistant organisms+1
1989
NDA30/100